Mirae Asset Sharekhan

📊 Q1FY2025 results review: sector-wise leaders summarized by Sharekhan research team Dive into the latest financial results as we break down the top performers across key sectors for Q1 of FY2025! Discover which companies have emerged as leaders and how they've driven growth in their respective industries. Swipe right to explore our comprehensive review and see what’s shaping the market this quarter! Disclaimer - http://rb.gy/14y35#Sharekhan #DesignedForTheSerious #Research #SharekhanKar #Q1FY2025 #Sharekhan #DesignedForTheSerious #Research #SharekhanKar #Q1FY2025

Q1FY25 Results Preview is here! 📈 Get expert insights from Sanjeev Hota on why domestic cyclicals are still driving growth despite a modest Nifty 50 outlook. Don't miss this crucial market update! Watch now 👉Hindi - https://youtu.be/d25-kQCoBQw?si=-TF-EVfd8rJ39Z1Y👉English - https://youtu.be/VbXZZ_mZGbU?si=OVkrgY1H7O4_Lf2aDisclaimer - http://rb.gy/14y35 #Q1FY25 #EarningsPreview #InvestmentTips #Sharekhan #Q1FY25 #EarningsPreview #InvestmentTips #Sharekhan

@sanjhota #Q1FY25 #EarningsPreview #InvestmentTips #Sharekhan #Q1FY25 #EarningsPreview #InvestmentTips #Sharekhan

#SharekhanResearch retains Buy rating on #Divis (12month PT Rs 4450) #Q1FY23 reslts missed est, encouraging growth… https://t.co/iPsNgGO74a #SharekhanResearch #Divis #Q1FY23

#SharekhanResearch retains Positive view on #CaplinPoint (Upside 20%) #Q1 was a strong quarter; focus to strengthen… https://t.co/WJhyG5RbY9 #SharekhanResearch #CaplinPoint #Q1

#SharekhanResearch #Q1FY23 Pharma Preview, India bizz gwth to be healthy while US bizz to be under pressure; high b… https://t.co/UrsYZaDh73 #SharekhanResearch #Q1FY23

#SharekhanResearch retains Buy on #SanofiIndia(PT Rs9250) #Q1CY22 strng qtr, focus on diabetology, gwth in top prdc… https://t.co/leABFh5zRR #SharekhanResearch #SanofiIndia #Q1CY22

#SharekhanResearch #Q1FY22 Pharma Review; healthy show, performance driven by strong growth in India bizz while hea… https://t.co/uMNA3Rmidz #SharekhanResearch #Q1FY22

#SharekhanResearch retains Buy rating on #Lupin (PT Rs1400) #Q1FY22 results marginally miss estimates; India bizz t… https://t.co/POnpFWZ49q #SharekhanResearch #Lupin #Q1FY22